SEATTLE, March 27, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the appointment of Patrick W. Gray, Ph.D. to the position of scientific fellow.
"Pat has an impressive track record of identifying commercially successful programs and products early in their development cycle," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "In his role as scientific fellow, Pat will be able to leverage his unique and deep expertise across our research and development matrix. We are pleased that he has joined our senior management team, and we look forward to him contributing to our success."
"The scientific depth and commercial potential of Omeros' programs are remarkable," stated Patrick W. Gray, Ph.D., Omeros' scientific fellow. "Omeros has a strong and experienced management team, and I look forward to helping the Company continue to transform its pipeline of programs into marketed products."
Dr. Gray brings to Omeros more than 30 years of experience in the biotechnology industry. He joined Omeros after serving from 2007 until 2012 as the chief scientific officer of Accelerator Corporation, a biotechnology-company investor and incubator affiliated with Amgen Ventures, ARCH Venture Partners, OVP Ventures Partners and the Institute for Systems Biology. Prior to Accelerator, Dr. Gray was the chief executive officer of nura, inc., a privately held biotechnology company acquired by Omeros in 2006. Before nura, he held senior scientific and management positions at Genentech, Inc., ICOS Corporation and MacroGenics, Inc.
Dr. Gray's career accomplishments include the first cloning and characterization of